Contribution: Industrial Research Assistance Program – Contributions to Firms
9397-2677 Québec inc.
$99,900.00
Development of an application for tissue microchip measurement.
EF 2024-25 · 2024-04-15
Résumé
The main human-derived tumor models (cell lines, xenografts and organoids) do not preserve the immune cells of the tumor from which they are derived. This limits the ability to effectively predict the effect of cancer immunotherapies in humans, and the ability to de-risk clinical validation. This project aims to characterize the immune microenvironment of human tumor explants and demonstrate its ability to measure an immune and cytotoxic response to a treatment applied ex vivo.
Ministère
Programme
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (lien de confiance élevée)
Bénéficiaire
Emplacement
Montreal|Montréal, Quebec, Canada
Type de bénéficiaire
For-profit organization
Numéro d'entreprise
773986138
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Tel que publié
Agreement End Date
2025-03-31
Agreement Number
1017172
Agreement Start Date
2024-04-15
Agreement Title
Development of an application for tissue microchip measurement.
Agreement Title (French)
Développement d’une application pour le mesure de tissu en micropuces.
Agreement Type
Contribution
Agreement Value
$99,900.00
Amendment Number
0
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
The main human-derived tumor models (cell lines, xenografts and organoids) do not preserve the immune cells of the tumor from which they are derived. This limits the ability to effectively predict the effect of cancer immunotherapies in humans, and the ability to de-risk clinical validation. This project aims to characterize the immune microenvironment of human tumor explants and demonstrate its ability to measure an immune and cytotoxic response to a treatment applied ex vivo.
Description (French)
Les principaux modèles tumoraux dérivés de l'humain (lignées cellulaires, xénogreffes et organoïdes) ne préservent pas les cellules immunitaires de la tumeur de laquelle ils sont dérivés. Cela limite la capacité à prédire efficacement l'effet des immunothérapies contre le cancer chez l'humain et la capacité à dé-risquer la validation clinique. Ce projet vise à caractériser le microenvironnement immunitaire d'explants tumoraux humains et démontrer sa capacité à mesurer une réponse immunitaire et cytotoxique d'un traitement appliqué ex vivo.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Papineau
Federal Riding (French)
Papineau
Federal Riding Number
24055
NAICS Code
54171
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
773986138
Recipient City
Montreal|Montréal
Recipient Country
CA
Recipient Legal Name
9397-2677 Québec inc.
Recipient Operating Name
MisoChip
Recipient Postal Code
H3N 1Y4
Recipient Province or Territory
QC
Recipient Type
F
Reference Number
172-2024-2025-Q1-1017172
